RPRM and gastric cancer: Finally, the strategy validated in MASPIN as proof of concept was later extended in a novel TSG, REPRIMO. This gene is relevant in gastric cancer and the methylation status of its promoter has been proposed as an effective biomarker [57, 58, 65].